(Q33770264)

29 July 2017

1 reference

title

Levodopa in Parkinson's disease: neurotoxicity issue laid to rest? (English)

1 reference

29 July 2017

1 reference

1 reference

1 reference

1 reference

M G Murer

1

1 reference

29 July 2017

R Raisman-Vozari

series ordinal

2

1 reference

29 July 2017

O Gershanik

series ordinal

3

1 reference

29 July 2017

publication date

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

21

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

339-352

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199921050-00001

29 July 2017

exact match

0 references

cites work

Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro

1 reference

12 December 2020

Concentrations of the water-soluble vitamins thiamin, ascorbic acid, and folic acid in serum and cerebrospinal fluid of healthy individuals

1 reference

12 December 2020

Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease

1 reference

12 December 2020

Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites.

1 reference

12 December 2020

Mortality of patients with parkinson's disease treated with levodopa

1 reference

12 December 2020

Response fluctuations in Parkinson's disease

1 reference

12 December 2020

The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression

1 reference

12 December 2020

Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.

1 reference

12 December 2020

Dopamine (3-hydroxytyramine) and brain function

1 reference

12 December 2020

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

1 reference

12 December 2020

1 reference

12 December 2020

Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.

1 reference

12 December 2020

Prolongation of the Life-Span in Mice Adapted to Large Amounts of L-Dopa

1 reference

12 December 2020

Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections

1 reference

12 December 2020

Neurotoxicity of levodopa on catecholamine-rich neurons

1 reference

12 December 2020

Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats.

1 reference

12 December 2020

Generation of reactive oxygen species by tyrosine hydroxylase: a possible contribution to the degeneration of dopaminergic neurons?

1 reference

12 December 2020

1 reference

12 December 2020

Chronic low-dose levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy

1 reference

12 December 2020

TOPA quinone, a kainate-like agonist and excitotoxin is generated by a catecholaminergic cell line.

1 reference

12 December 2020

Toxic and protective effects of L-dopa on mesencephalic cell cultures

1 reference

12 December 2020

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease

1 reference

12 December 2020

N-methyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early marker of Parkinson's disease.

1 reference

12 December 2020

Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line

1 reference

12 December 2020

Chronic dopa feeding of mice.

1 reference

12 December 2020

Adjuncts to levodopa therapy: dopamine agonists

1 reference

12 December 2020

Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage

1 reference

12 December 2020

Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral Inhibitor

1 reference

12 December 2020

Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice.

1 reference

12 December 2020

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

1 reference

12 December 2020

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

1 reference

12 December 2020

History of levodopa and dopamine agonists in Parkinson's disease treatment.

1 reference

12 December 2020

Dopamine neurotoxicity in cortical neurons.

1 reference

12 December 2020

Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms

1 reference

12 December 2020

Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease.

1 reference

12 December 2020

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

1 reference

12 December 2020

The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.

1 reference

12 December 2020

Should levodopa therapy be started early or late?

1 reference

12 December 2020

L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?

1 reference

12 December 2020

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

1 reference

12 December 2020

Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice

1 reference

12 December 2020

Multi-center study of Parkinson mortality with early versus later dopa treatment

1 reference

12 December 2020

Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued

1 reference

12 December 2020

Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project

1 reference

12 December 2020

Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease

1 reference

12 December 2020

Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients

1 reference

12 December 2020

Nigrostriatal Dopaminergic Neurons Remain Undamaged in Rats Given High Doses of l-DOPA and Carbidopa Chronically

1 reference

12 December 2020

Oxidation reactions in Parkinson's disease.

1 reference

12 December 2020

Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease.

1 reference

12 December 2020

Parkinson's disease: progression and mortality

1 reference

12 December 2020

Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine.

1 reference

12 December 2020

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

1 reference

12 December 2020

Evidence for an antiapoptotic role of dopamine in developing retinal tissue

1 reference

12 December 2020

Levodopa in Parkinson disease: a long-term appraisal of mortality

1 reference

12 December 2020

Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA.

1 reference

12 December 2020

1 reference

12 December 2020

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

1 reference

12 December 2020

Dopa and dopamine cause cultured neuronal death in the presence of iron

1 reference

12 December 2020

Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid.

1 reference

12 December 2020

Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease

1 reference

12 December 2020

Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease

1 reference

12 December 2020

Dopamine neurotoxicity: inhibition of mitochondrial respiration

1 reference

12 December 2020

Modification of Parkinsonism--chronic treatment with L-dopa

1 reference

12 December 2020

Monoamine oxidase, dopamine and Parkinson's disease

1 reference

12 December 2020

Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons

1 reference

12 December 2020

Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats

1 reference

12 December 2020

Does levodopa aggravate Parkinson's disease?

1 reference

12 December 2020

Timely levodopa (LD) administration prolongs survival in Parkinson's disease

1 reference

12 December 2020

Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro

1 reference

12 December 2020

L-dopa cytotoxicity to PC12 cells in culture is via its autoxidation.

1 reference

12 December 2020

1 reference

12 December 2020

Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates

1 reference

12 December 2020

Parkinson's disease: follow-up after "drug holiday"

1 reference

12 December 2020

Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys

1 reference

12 December 2020

Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease

1 reference

12 December 2020

Mortality from Parkinson disease.

1 reference

12 December 2020

Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection.

1 reference

12 December 2020

"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

1 reference

12 December 2020

Parkinson's disease in Aberdeen: survival after 3.5 years.

1 reference

12 December 2020

Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases

1 reference

12 December 2020

Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione

1 reference

12 December 2020

Levodopa induces apoptosis in cultured neuronal cells--a possible accelerator of nigrostriatal degeneration in Parkinson's disease?

1 reference

12 December 2020

A vitamin as neuromodulator: ascorbate release into the extracellular fluid of the brain regulates dopaminergic and glutamatergic transmission

1 reference

12 December 2020

Complications of chronic levodopa therapy: long-term efficacy of drug holiday

1 reference

12 December 2020

Death rates from Parkinson's disease in Norway reflect increased survival

1 reference

12 December 2020

Considerations in the management of parkinsonism

1 reference

12 December 2020

The effect ofl-DOPA and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography

1 reference

12 December 2020

Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period.

1 reference

12 December 2020

Mitochondrial complex I deficiency in Parkinson's disease

1 reference

12 December 2020

Lipid Peroxidation in Brain: Interactions of L-DOPA/Dopamine with Ascorbate and Iron

1 reference

12 December 2020

Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease

1 reference

12 December 2020

Dopamine increases the expression of tyrosine hydroxylase and aromatic amino acid decarboxylase in primary cultures of fetal neurons

1 reference

12 December 2020

L-DOPA is a substrate for tyrosine hydroxylase

1 reference

12 December 2020

Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa

1 reference

12 December 2020

Age at onset: the major determinant of outcome in Parkinson's disease.

1 reference

12 December 2020

Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients.

1 reference

12 December 2020

L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells

1 reference

12 December 2020

Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures.

1 reference

12 December 2020

Enzymatic oxidation of dopamine: the role of prostaglandin H synthase

1 reference

12 December 2020

Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

1 reference

12 December 2020

Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys

1 reference

12 December 2020

L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress.

1 reference

12 December 2020

Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons

1 reference

12 December 2020

Pergolide in the treatment of Parkinson's disease.

1 reference

12 December 2020

1 reference

12 December 2020

Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones

1 reference

12 December 2020

Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy

1 reference

12 December 2020

An endogenous dopaminergic neurotoxin: implication for Parkinson's disease

1 reference

12 December 2020

Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture.

1 reference

12 December 2020

Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment

1 reference

12 December 2020

Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?

1 reference

12 December 2020

Morphogenic potentials of D2, D3, and D4 dopamine receptors revealed in transfected neuronal cell lines

1 reference

12 December 2020

The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence

1 reference

12 December 2020

1 reference

12 December 2020

L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects

1 reference

12 December 2020

Evidence to support early levodopa therapy in Parkinson disease

1 reference

12 December 2020

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

1 reference

12 December 2020

Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations

1 reference

12 December 2020

Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease

1 reference

12 December 2020

Factors that influence the occurrence of response variations in Parkinson's disease

1 reference

12 December 2020

Does levodopa therapy delay death in Parkinson's disease? A review of the evidence.

1 reference

12 December 2020

Ascorbic acid in mesencephalic cultures: effects on dopaminergic neuron development.

1 reference

12 December 2020

Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor

1 reference

12 December 2020

Genetic toxicity of dopamine.

1 reference

12 December 2020

Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity

1 reference

12 December 2020

Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine

1 reference

12 December 2020

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

12 December 2020

Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons

1 reference

12 December 2020

Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease

1 reference

12 December 2020

Is levodopa toxic to human substantia nigra?

1 reference

12 December 2020

Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity.

1 reference

12 December 2020

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

1 reference

12 December 2020

1 reference

12 December 2020

Cellular defenses against damage from reactive oxygen species

1 reference

12 December 2020

Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group

1 reference

12 December 2020

Mortality associated with early and late levodopa therapy initiation in Parkinson's disease

1 reference

12 December 2020

10.2165/00002018-199921050-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1041918151

0 references

1 reference